Pioneering a novel macrophage conditioning approach to deliver breakthrough cancer therapies

Pathios Therapeutics is an early-stage drug discovery company targeting a genetically-validated innate immune checkpoint as an approach to unleashing the power of macrophages in the fight against cancer

Find out more

At Pathios we are leveraging a proprietary knowledge of macrophage biology and innate immune checkpoints based on human genetics, single cell transcriptomics and functional cellular immunology to deliver first-in-class and best-in-class therapies for advanced cancers


Pioneering macrophage conditioning to unlock the power of the innate immune system against cancer

The acidic tumour microenvironment inherent to many cancers causes a profound immunosuppression of infiltrating immune cells. This disarms the anti-cancer immune response and negates the effectiveness of current immunotherapies. This is particularly evident in tumour associated macrophages (TAMs), where acidity is sensed by the cell-surface receptor, GPR65, leading to an induction of the transcriptional repressor, ICER (inducible cAMP early repressor), and the widespread suppression of pro-inflammatory mediators such as TNFα, IL-6 and IL-12. Pathios is developing drugs to block GPR65 and prevent this signalling, thereby conditioning macrophages toward a pro-inflammatory, immune-stimulating phenotype that can reignite an effective anti-tumour immune response and harness the power of the innate immune system against cancer.


Learn more about Pathios and our pursuit of groundbreaking therapies.

Pathios is based in Oxford, UK and brings together a team of experienced scientific leaders to deliver new therapies in autoimmune diseases and cancer. Read about recent developments here.

Pathios' AACR 2022 Presentation

Inhibition of GPR65 counteracts low pH induced immunosuppressive polarization of macrophages: In vitro and in vivo characterization of potent, selective and orally bioavailable small molecule GPR65 antagonists.